IL1B and rheumatoid arthritis: Taken together, we can conclude that the primary active ingredients in STZY are likely to modulate RA via their anti-inflammatory effects, and that these effects are likely to be focused on the modulation of various inflammatory factors such as IL-1β, IL-1α, IL-2, IL-4, IL-6, and IL-10.